Clinical Trial Update: Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs [Phase 2]

View source ↗

Summary

Phase II study results update for continuous dosing of regorafenib in patients with gastrointestinal stromal tumors (GISTs).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Asan Medical Center | Conditions: Gastrointestinal Stromal Tumors (GISTs) | Phase 2 | Status: COMPLETED